07:22 AM EDT, 07/17/2025 (MT Newswires) -- GSK (GSK) said Thursday that the US Food and Drug Administration has approved a prefilled syringe version of Shingrix, a vaccine for the prevention of shingles.

The syringe removes the need to assemble vials before injection, simplifying vaccine administration, the company said.

The prefilled syringe is licensed in the US for immunization of adults aged 50 years and older, as well as those aged 18 years and older at increased risk of shingles due to immunodeficiency or immunosuppression caused disease or therapy, the company said.

GSK said the prefilled syringe is also undergoing regulatory review by the European Medicines Agency and that it is also exploring submission in other markets.